Publications by authors named "Christos Emmanouilidis"
The growth of the Internet of Things (IoT) offers numerous opportunities for developing industrial applications such as smart grids, smart cities, smart manufacturers, etc. By utilising these opportunities, businesses engage in creating the Industrial Internet of Things (IIoT). IoT is vulnerable to hacks and, therefore, requires various techniques to achieve the level of security required.
View Article and Find Full Text PDFThe Internet of Things (IoT) has significant potential in upgrading legacy production machinery with monitoring capabilities to unlock new capabilities and bring economic benefits. However, the introduction of IoT at the shop floor layer exposes it to additional security risks with potentially significant adverse operational impact. This article addresses such fundamental new risks at their root by introducing a novel endpoint security-by-design approach.
View Article and Find Full Text PDFArticle Synopsis
- There is a gap in following international guidelines for managing metastatic colorectal cancer (CRC) in Greece and Cyprus, prompting the need for a new consensus on treatment strategies.
- An executive team from the Hellenic Society of Medical Oncology collaborated with international experts using the Delphi methodology to develop and vote on 109 statements regarding CRC management.
- The final consensus highlights the importance of a centralized approach, multidisciplinary care, adherence to guidelines, patient personalization, and that R0 resection is key for better oncological outcomes.
In rectal cancer management, accurate staging by magnetic resonance imaging, neo-adjuvant treatment with the use of radiotherapy, and total mesorectal excision have resulted in remarkable improvement in the oncological outcomes. However, there is substantial discrepancy in the therapeutic approach and failure to adhere to international guidelines among different Greek-Cypriot hospitals. The present guidelines aim to aid the multidisciplinary management of rectal cancer, considering both the local special characteristics of our healthcare system and the international relevant agreements (ESMO, EURECCA).
View Article and Find Full Text PDFArticle Synopsis
- There is significant variation in colon cancer outcomes across European countries, particularly in Greece and Cyprus, largely due to differing management strategies and guideline adherence.
- A consensus for multidisciplinary colon cancer management was created based on European guidelines, involving extensive discussions and a structured Delphi voting process among international experts.
- Ultimately, the consensus included 60 statements on colon cancer management, achieving over 80% agreement, highlighting the need for centralized care, multidisciplinary teamwork, and strict adherence to established guidelines.
Colorectal cancer remains a major cause of cancer mortality in the Western world both in men and women. In this manuscript a concise overview and recommendations on adjuvant chemotherapy in colon cancer are presented. An executive team from the Hellenic Society of Medical Oncology was assigned to develop a consensus statement and guidelines on the adjuvant treatment of colon cancer.
View Article and Find Full Text PDFPurpose: To evaluate the safety and antitumor activity of docetaxel (DOC) and pegylated liposomal doxorubicin (PLD) combination in patients with platinum- and taxane-sensitive ovarian cancer.
Patients And Methods: Twenty-three patients were enrolled. DOC was administered at the dose of 40 mg/m(2) intravenously (i.
Introduction: Therapeutic options for patients with relapsed, chemo-resistant small-cell lung cancer (SCLC) are limited. Since paclitaxel has demonstrated single-agent activity in the second-line setting of SCLC and angiogenesis seems to play an important role in the pathogenesis of the disease, a phase II trial was conducted in order to evaluate the efficacy and the tolerance of their combination in patients with relapsed, chemo-resistant SCLC.
Patients And Methods: Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 who experienced relapse within 3 months after completion of 1st line chemotherapy for SCLC were eligible.